Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Cost-effectiveness analysis of universal newborn screening for medium chain acyl-CoA dehydrogenase deficiency in France.

Hamers FF, Rumeau-Pichon C.

BMC Pediatr. 2012 Jun 8;12:60. doi: 10.1186/1471-2431-12-60.

2.

Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis.

Venditti LN, Venditti CP, Berry GT, Kaplan PB, Kaye EM, Glick H, Stanley CA.

Pediatrics. 2003 Nov;112(5):1005-15.

PMID:
14595039
3.

Projected costs, risks, and benefits of expanded newborn screening for MCADD.

Prosser LA, Kong CY, Rusinak D, Waisbren SL.

Pediatrics. 2010 Feb;125(2):e286-94. doi: 10.1542/peds.2009-0605.

PMID:
20123779
4.

Clinical efficacy and cost-effectiveness of newborn screening for medium chain acyl-CoA dehydrogenase deficiency using tandem mass spectrometry.

Tran K, Banerjee S, Li H, Noorani HZ, Mensinkai S, Dooley K.

Clin Biochem. 2007 Feb;40(3-4):235-41. Epub 2006 Dec 5.

PMID:
17222812
6.

The first three years of screening for medium chain acyl-CoA dehydrogenase deficiency (MCADD) by newborn screening ontario.

Kennedy S, Potter BK, Wilson K, Fisher L, Geraghty M, Milburn J, Chakraborty P.

BMC Pediatr. 2010 Nov 17;10:82. doi: 10.1186/1471-2431-10-82.

7.

Cost-effectiveness of neonatal screening for medium chain acyl-CoA dehydrogenase deficiency: the homogeneous population of The Netherlands.

van der Hilst CS, Derks TG, Reijngoud DJ, Smit GP, TenVergert EM.

J Pediatr. 2007 Aug;151(2):115-20, 120.e1-3.

PMID:
17643759
8.

An Economic Evaluation of Neonatal Screening for Inborn Errors of Metabolism Using Tandem Mass Spectrometry in Thailand.

Thiboonboon K, Leelahavarong P, Wattanasirichaigoon D, Vatanavicharn N, Wasant P, Shotelersuk V, Pangkanon S, Kuptanon C, Chaisomchit S, Teerawattananon Y.

PLoS One. 2015 Aug 10;10(8):e0134782. doi: 10.1371/journal.pone.0134782. eCollection 2015.

9.

Expanding screening for rare metabolic disease in the newborn: an analysis of costs, effect and ethical consequences for decision-making in Finland.

Autti-Rämö I, Mäkelä M, Sintonen H, Koskinen H, Laajalahti L, Halila R, Kääriäinen H, Lapatto R, Näntö-Salonen K, Pulkki K, Renlund M, Salo M, Tyni T.

Acta Paediatr. 2005 Aug;94(8):1126-36.

PMID:
16188860
10.

Newborn screening for medium chain acyl-CoA dehydrogenase deficiency (MCADD) in the UK.

Goddard P.

J Fam Health Care. 2004;14(4):90-2. Review.

PMID:
15453442
11.

Newborn screening for medium chain acyl-CoA dehydrogenase deficiency in England: prevalence, predictive value and test validity based on 1.5 million screened babies.

Oerton J, Khalid JM, Besley G, Dalton RN, Downing M, Green A, Henderson M, Krywawych S, Leonard J, Andresen BS, Dezateux C.

J Med Screen. 2011;18(4):173-81. doi: 10.1258/jms.2011.011086. Epub 2011 Dec 13.

12.

Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review.

Pandor A, Eastham J, Beverley C, Chilcott J, Paisley S.

Health Technol Assess. 2004 Mar;8(12):iii, 1-121. Review.

13.

Prevalence and mutation analysis of short/branched chain acyl-CoA dehydrogenase deficiency (SBCADD) detected on newborn screening in Wisconsin.

Van Calcar SC, Baker MW, Williams P, Jones SA, Xiong B, Thao MC, Lee S, Yang MK, Rice GM, Rhead W, Vockley J, Hoffman G, Durkin MS.

Mol Genet Metab. 2013 Sep-Oct;110(1-2):111-5. doi: 10.1016/j.ymgme.2013.03.021. Epub 2013 Apr 15.

14.

Ethnicity of children with homozygous c.985A>G medium-chain acyl-CoA dehydrogenase deficiency: findings from screening approximately 1.1 million newborn infants.

Khalid JM, Oerton J, Cortina-Borja M, Andresen BS, Besley G, Dalton RN, Downing M, Green A, Henderson M, Leonard J, Dezateux C; UK Collaborative Study of Newborn Screening for MCADD.

J Med Screen. 2008;15(3):112-7. doi: 10.1258/jms.2008.008043.

PMID:
18927092
15.

Medium-chain acyl-CoA dehydrogenase deficiency in Saudi Arabia: incidence, genotype, and preventive implications.

Al-Hassnan ZN, Imtiaz F, Al-Amoudi M, Rahbeeni Z, Al-Sayed M, Al-Owain M, Al-Zaidan H, Al-Odaib A, Rashed MS.

J Inherit Metab Dis. 2010 Dec;33 Suppl 3:S263-7. doi: 10.1007/s10545-010-9143-1. Epub 2010 Jun 22.

PMID:
20567907
16.

MCAD deficiency in Denmark.

Andresen BS, Lund AM, Hougaard DM, Christensen E, Gahrn B, Christensen M, Bross P, Vested A, Simonsen H, Skogstrand K, Olpin S, Brandt NJ, Skovby F, Nørgaard-Pedersen B, Gregersen N.

Mol Genet Metab. 2012 Jun;106(2):175-88. doi: 10.1016/j.ymgme.2012.03.018. Epub 2012 Apr 4.

PMID:
22542437
17.

Newborn screening with tandem mass spectrometry: examining its cost-effectiveness in the Wisconsin Newborn Screening Panel.

Insinga RP, Laessig RH, Hoffman GL.

J Pediatr. 2002 Oct;141(4):524-31. Erratum in: J Pediatr. 2003 Jan;142(1):56..

PMID:
12378192
18.

Data mining methods for classification of Medium-Chain Acyl-CoA dehydrogenase deficiency (MCADD) using non-derivatized tandem MS neonatal screening data.

Van den Bulcke T, Vanden Broucke P, Van Hoof V, Wouters K, Vanden Broucke S, Smits G, Smits E, Proesmans S, Van Genechten T, Eyskens F.

J Biomed Inform. 2011 Apr;44(2):319-25. doi: 10.1016/j.jbi.2010.12.001. Epub 2010 Dec 15.

19.

The epidemiology of medium chain acyl-CoA dehydrogenase deficiency: an update.

Grosse SD, Khoury MJ, Greene CL, Crider KS, Pollitt RJ.

Genet Med. 2006 Apr;8(4):205-12. Review.

PMID:
16617240
20.

Neonatal screening for inborn errors of metabolism: cost, yield and outcome.

Pollitt RJ, Green A, McCabe CJ, Booth A, Cooper NJ, Leonard JV, Nicholl J, Nicholson P, Tunaley JR, Virdi NK.

Health Technol Assess. 1997;1(7):i-iv, 1-202. Review.

Supplemental Content

Support Center